Neucore Bio
PrivateLast Round
Grant
Sep 2, 2025
Total Funding Raised
$4.7M
Company Overview
Neucore Bio is a biotechnology company developing a pipeline of first-in-class antibody-based therapeutics to treat neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neucore Bio Comparables
Compare Neucore Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| STRM.BIO | 83% | |
| Carmine Therapeutics | 81% | |
| Vesigen Therapeutics | 81% |
Neucore Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 2, 2025 | ||||
| Grant | Aug 6, 2025 | ||||
| Seed | Feb 6, 2024 | ||||
| Grant | Jul 11, 2023 |
Key People
Founding team and executive leadership
Neucore Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ohio State University | Seed |
| Ohio Third Frontier | Grant |
| National Center for Advancing Translational Sciences | Grant |
| National Institutes of Health (NIH) | Grant |
| CincyTech | Seed |
| National Science Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 17, 2026
Monthly visitors grew 210% MoM, from 287 to 889.
- Jan 6, 2026
Monthly visitors grew 71% MoM.
Neucore Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Neucore Bio's valuation, stock price, and market status.
Is Neucore Bio a public or private company?
Neucore Bio is a private company.
What is the current stock price of Neucore Bio?
Neucore Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Neucore Bio worth (valuation)?
Valuation information for Neucore Bio is not publicly available.
Can I buy Neucore Bio stock?
Neucore Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Neucore Bio's last funding round?
Neucore Bio's most recent funding round was Grant on September 2, 2025.
Who are the main investors in Neucore Bio?
Key investors in Neucore Bio include Ohio State University, Ohio Third Frontier, National Center for Advancing Translational Sciences, National Institutes of Health (NIH), CincyTech.
Will Neucore Bio IPO soon?
No public IPO plans have been announced for Neucore Bio.
How can I track Neucore Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Neucore Bio's secondary market activity and sign up for updates.